AzTrials
AzTrials

IUD (Intrauterine Device) MalpositionNCT05624411

Clinical Outcomes of Post-placental Insertion of Cupper T380A and Multiload 375 Contraceptive Devices During Cesarean Section

An observational study of IUD (Intrauterine Device) Malposition and IUD; Complications, Infection or Inflammation, run by Sohag University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Clinical outcomes of post-placental insertion of Cupper T380A and Multiload 375 contraceptive devices during cesarean section Read more about this study

Who is it for?
Ages 18 to 45 years, women only
What is being tested?
CU T380A IUD and multiload 375 IUD
Type of treatment
Medical device
How many people
150 participants
Where
1 siteEgypt
Study dates
22 Oct 2022to 1 Sep 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • Adult

Study population: All patients admitted for delivery at obstetric and gynecology emergency unit of sohag university hospital which is a tertiary center at sohag city in egypt who requested postpartum contraception, were invited to participate in the study

Who may be able to join

  • -(1) All patients admitted for delivery at our department who requested postpartum contraception, were invited to participate in the study.
  • Age (18-45)

Who cannot join

  • (1) Intrauterine infection at time of delivery (chorioamnionitis) (2) postpartum hemorrhage (3) Uterine anomalies (distorted uterine cavity) (4) History of previous IUD expulsion (5) Anemic patients with hemoglobin< 10gm/dl (6) pre-labor rupture of membranes for more than 18 hours (7) Placenta previa.

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Sohag University

    Sohag

Other trials in Egypt

About this study

Clinical outcomes of post-placental insertion of Cupper T380A and Multiload 375 contraceptive devices during cesarean section

Read the detailed description

An intrauterine device (IUD) is considered one of the most effective, highly convenient and cheap methods of contraception[1]. IUD has been endorsed as a first-line contraceptive choice by the American College of Obstetricians and Gynecologists [2]. However, many complications have been reported with its use, such as irregular bleeding, expulsion, pelvic pain, and unexpected pregnancy.

Furthermore, extrauterine migration of IUD may result in damage to adjacent organs, bowel injury or even death [3]. Well-designed studies have elucidated that uterine perforation is expected in 0.2 to 3.6 per 1000 IUD insertions [4]. In addition, some case reports have shown IUD displacement into the sigmoid colon and lower urinary tract [5-8].

Nearly, fifty percent of malpositioned IUDs are asymptomatic and usually undetected for many years. Taking into consideration the possible risk of extrauterine migration and its dangerous sequelas, follow-up examinations are advised for all women after IUD insertion [9].

One of the safe, trusted and most convenient strategies to avoid new unwanted pregnancies is immediate postpartum IUD placement, within 10 minutes of delivery of the placenta [10]. However, expulsion rates are higher after immediate postpartum IUD insertions in comparison to delayed postpartum insertions (4-6 weeks postpartum)[11-13] Ultrasonographic assessment is considered the standard tool for confirming the position of an IUD.

  1. Aim of the study The aim of the current study is to compare two types of intrauterine devices, namely Cu T380A IUD and Multiload 375 IUD, inserted immediately post placental, as regard to expulsion rates, safety, efficacy, side effects, and complications.
  2. Subjects and Methods
  3. Study type: A randomized comparative clinical trial 4) Methods: This study is a clinical trial that will include all patients fulfilling the eligibility criteria and presented to the emergency unit of the department of Obstetrics and Gynecology at Sohag University hospital (Egyptian tertiary referral hospital) who are requesting immediate postpartum contraception between November 2022 and September 2023. The attending physician will explain the nature of the study and all patients included will be asked to sign an informed consent. Participants were randomly allocated through a computer-generated list into two groups. In the first group Cu-T380A (Pregna International Ltd) will be inserted while in the second group Multiload 375 (Pregna International Ltd, Mumbai, India) will be inserted, Researchers and participants will not be masked to the type of IUCD inserted.

IUCDs will be inserted high at the fundus through the lower uterine segment incision immediately after delivery of the placenta using the cylinder provided within the sterile packaging; the IUCD pushing rod will not be used. Before placement in the uterine cavity, both IUCD strings were lengthened using 10 cm of Vicryl sutures (polyglactin 910) number 0 which will then threaded through the cylinder to appear at the other end. Following insertion adjacent to the fundus, the cylinder will be gradually moved downwards across the threads, passed through the cervix, and removed vaginally after delivery [14], This technique ensures that the threads are located within the vagina immediately after the operation and prevents their entanglement within the cervical canal or uterine cavity[14]. The uterine incision will then be closed in two layers.

Transabdominal US will be done to all patients before discharge to ensure adequate position of the IUD and then Women will be requested to attend follow-up appointment at 6 weeks after delivery, gynecological examination in addition to transvaginal sonography will be done to measure top-fundal distance that reflects the position of the IUD. The participants were instructed to report the pattern of bleeding during the puerperium, the number of sanitary pads used per day, the presence of blood clots, missed periods, fever, or vaginal discharge. They were shown how to find the threads and informed to urgently seek medical care if they could not feel the threads. During the puerperium, the Vicryl suture knot appeared below the cervix; the threads were shortened to a length of 2 cm from the cervix. Transabdominal and transvaginal 2D ultrasonography will be used to evaluate IUCD position in each visit. Complete expulsion was recorded when the longitudinal arm of the IUCD was partially or totally inside the cervix or vagina. Partial expulsion or displacement was recorded when the IUCD was more than 10 mm away from the fundus but still totally within the uterine cavity [15]. Women with severe PID who did not respond to treatment and/or had severe menorrhagia were candidates for IUCD discontinuation and were prescribed another contraception method if required.

  1. Statistical analysis: Data will be expressed as mean ± standard deviation (SD), unless stated otherwise. Chi-squared test will be used to compare categorical variables and Student's t-test to compare continuous variables. A p-value of <0.05 will be considered statistically significant. STATA v14 (StataCorp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP) and MedCalc programs and will be used for data analysis.
  2. Study results and impact: The current study may prove or disprove the benefits versus the risks of intrapartum insertion of different types of IUCDs.
Being tested
CU T380A IUD, multiload 375 IUD
Keywords
postplacental IUD, IUD, Cupper T380A IUD, Multiload 375 IUD, iud expulsion
Medical subject headings
Infections, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CU T380A IUDDevice

    Also called CU T380A

    post-placental insertion of intrauterine contraceptive device

  • multiload 375 IUDDevice

    Also called multiload 375

    post-placental insertion of intrauterine contraceptive device

Study groups in NCT05624411
Study groupRoleWhat they receive
Apost-placental insertion of CU T380A IUD during CS
Receives: Device: CU T380A IUD
Bpost-placental insertion of multiload 375 IUD during CS
Receives: Device: multiload 375 IUD

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The expulsion rate of Multiload IUCD versus CopperT380A after post-placental insertion

    The expulsion rate of Multiload IUCD versus CopperT380A after post-placental insertion

    Measured: 6 weeks

Secondary outcomes (6)
  1. Uterine bleeding

    number of bleeding days

    Measured: 6 weeks

  2. Uterine bleeding

    pattern of bleeding

    Measured: 6 weeks

  3. Uterine bleeding

    presence of blood clots

    Measured: 6 weeks

  4. PID

    pesence of fever or vaginal discharge

    Measured: 6 weeks

  5. perforation

    presence of abdominal pain

    Measured: 6 weeks

  6. pregnancy on top of IUCD

    missed periods , or pregnancy

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Nov 2022
  2. Study start22 Oct 2022
  3. Primary completion1 Sep 2023 (estimated)
  4. Study completion1 Sep 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05624411
Sponsor's protocol ID
soh-Med-22-11-03
Status last verified
Nov 2022
First submitted
21 Oct 2022
Last updated
22 Nov 2022
Results posted
No
FDA-regulated device
Yes

Publications

  • Bilian X. Chinese experience with intrauterine devices. Contraception. 2007 Jun;75(6 Suppl):S31-4. doi: 10.1016/j.contraception.2006.12.007. Epub 2007 Feb 16.

    PubMed 17531613
  • Hillard PJ. Practical tips for intrauterine devices use in adolescents. J Adolesc Health. 2013 Apr;52(4 Suppl):S40-6. doi: 10.1016/j.jadohealth.2012.09.023.

    PubMed 23535056
  • Behtash N, Akhavan S, Mokhtar S. Pelvic mass due to transmigrated IUD. Acta Med Iran. 2010 Mar-Apr;48(2):125-6.

    PubMed 21133007
  • Vasquez P, Schreiber CA. The missing IUD. Contraception. 2010 Aug;82(2):126-8. doi: 10.1016/j.contraception.2010.02.019. Epub 2010 Apr 2. No abstract available.

    PubMed 20654751
  • Ko PC, Lin YH, Lo TS. Intrauterine contraceptive device migration to the lower urinary tract: report of 2 cases. J Minim Invasive Gynecol. 2011 Sep-Oct;18(5):668-70. doi: 10.1016/j.jmig.2011.05.010.

    PubMed 21872173
  • Kus E, Swierczewski A, Pasinski J, Estemberg D, Brzozowska M, Kowalska-Koprek U, Berner-Trabska M, Karowicz-Bilinska A. [Intrauterine contraceptive device in an appendix--a case report]. Ginekol Pol. 2012 Feb;83(2):132-5. Polish.

    PubMed 22568359
  • Taras AR, Kaufman JA. Laparoscopic retrieval of intrauterine device perforating the sigmoid colon. JSLS. 2010 Jul-Sep;14(3):453-5. doi: 10.4293/108680810X12924466006684.

    PubMed 21333209
  • Vilallonga R, Rodriguez N, Vilchez M, Armengol M. Translocation of an intrauterine contraceptive device: incidental finding in the rectosigmoid colon. Obstet Gynecol Int. 2010;2010:404160. doi: 10.1155/2010/404160. Epub 2010 Jun 9.

    PubMed 20613996
  • Koltan SO, Tamay AG, Yildirim Y. Chronic cervical perforation by an intrauterine device. J Chin Med Assoc. 2010 Jun;73(6):325-6. doi: 10.1016/S1726-4901(10)70069-1.

    PubMed 20603091
  • American College of Obstetricians and Gynecologists' Committee on Obstetric Practice. Committee Opinion No. 670: Immediate Postpartum Long-Acting Reversible Contraception. Obstet Gynecol. 2016 Aug;128(2):e32-7. doi: 10.1097/AOG.0000000000001587.

    PubMed 27454734
  • Whitaker AK, Chen BA. Society of Family Planning Guidelines: Postplacental insertion of intrauterine devices. Contraception. 2018 Jan;97(1):2-13. doi: 10.1016/j.contraception.2017.09.014. Epub 2017 Oct 5.

    PubMed 28987293
  • Lopez LM, Bernholc A, Hubacher D, Stuart G, Van Vliet HA. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database Syst Rev. 2015 Jun 26;2015(6):CD003036. doi: 10.1002/14651858.CD003036.pub3.

    PubMed 26115018
  • Averbach SH, Ermias Y, Jeng G, Curtis KM, Whiteman MK, Berry-Bibee E, Jamieson DJ, Marchbanks PA, Tepper NK, Jatlaoui TC. Expulsion of intrauterine devices after postpartum placement by timing of placement, delivery type, and intrauterine device type: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020 Aug;223(2):177-188. doi: 10.1016/j.ajog.2020.02.045. Epub 2020 Mar 3.

    PubMed 32142826
  • Nelson AL, Chen S, Eden R. Intraoperative placement of the Copper T-380 intrauterine devices in women undergoing elective cesarean delivery: a pilot study. Contraception. 2009 Jul;80(1):81-3. doi: 10.1016/j.contraception.2009.01.014. Epub 2009 Mar 4.

    PubMed 19501220
  • Mosley FR, Shahi N, Kurer MA. Elective surgical removal of migrated intrauterine contraceptive devices from within the peritoneal cavity: a comparison between open and laparoscopic removal. JSLS. 2012 Apr-Jun;16(2):236-41. doi: 10.4293/108680812x13427982377265.

    PubMed 23477171

Questions about this trial

What is this clinical trial studying?

An observational study of IUD (Intrauterine Device) Malposition and IUD; Complications, Infection or Inflammation, run by Sohag University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The expulsion rate of Multiload IUCD versus CopperT380A after post-placental insertion (time frame: 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05624411, which also lists 15 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Nov 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in